National and Kapodistrian University of Athens
Ανοσοθεραπεία καρκίνου: ανοσολογικές παράμετροι ως βιολογικοί δείκτες ανταπόκρισης ασθενών με καρκίνο
Abstract
dc:descriptionIdentification of tumor associated antigens (TAAs) contributed to the development of the peptide cancer vaccines, as a novel therapeutic approach in cancer. Clinical trials have shown promising results, though to a limited number of patients. Important limitations involve the multifunctionality of the immune system along with its interaction with the tumor, as well as the inappropriate clinical design. As far as the immune system is concerned, new therapeutic strategies combine inhibition of immunosuppressive elements, which usually flourish in tumor microenvironment, along with boosting of antitumor immune responses. Understanding how the immune system interacts with the tumor, leads to the improvement of the applied therapeutic approaches. On the other hand, cancer vaccine trials have failed to accomplish significant clinical responses due to the erroneous clinical design. Patient selection, as well as, the determination of the appropriate primary endpoints and immunologic monitoring are essential to successfully evaluate cancer vaccines and bring them to clinical use. Patient selection is an important procedure, since it indicates patients that could benefit from a specific treatment, hence contributing to the avoidance of overtreatment. The aim of the present dissertation is to suggest possible prognostic/predictive biomarkers for patient selection, based on the results of two immunotherapeutic clinical protocols with the HER2 peptide vaccine AE37. The AE37 vaccine consists of the native HER2 peptide ΑΕ36 (HER2(776-790)) chemically linked to the Ii-key (LRMK), a modification that actually enhances antigen presentation. Previous repots have shown that AE37 vaccine is safe and well tolerated, capable of inducing both CD4+ and CD8+ cellular immune responses in patients with HER2+ prostate or breast cancer. Results from the phase I clinical trial in prostate cancer patients showed that the AE37 can induce HER2 specific immune responses that could be detected even 3 years after the last inoculations. Retrospective analyses in the same patients, showed that preexisting levels of HER2 immunity and TGFβ plasma levels before the first inoculation, might have a prognostic role in the immunologic as well as clinical response in patients vaccinated with the AE37 peptide vaccine. More specifically, increased levels of preexisting IFNγ immunity in response to the native peptide AE36, correlated with better immunological response to the AE37 vaccine and better overall survival. However, elevated levels of TGFβ, an immunosuppressive factor, correlated with lower immunological responses and worse overall survival. Beside this, the magnitude of the DTH reaction seems to positively correspond to both immunological and clinical response. Given the fact that HLA molecules are considered genetic restricted elements, that indicate T cellular antitumor immune responses, we investigated the expression of HLA-A*24 and HLA-DRB1*11, in the context novel biomarkers’ identification. Even though the above mentioned alleles are rather common in Greek population, the percentage of patients expressing these alleles, and primarily HLA-A*24, was higher in prostate cancer patients who vaccinated with the AE37 and survived up to 4 years post initial diagnosis. Beside that the native AE36 exerts high binding affinity to HLA-DRB1*11, it also encompasses ΜΗC class I epitopes, including HLA-A*24. Our findings provide evidence that HLA-A*24 and HLA-DRB1*11 alleles might serve as biomarkers of the immunologic and clinical response, further contributing in effective selection of patients, that could gain benefit from the specific treatment. Moreover, we detected AE37 vaccine-induced CD4+ T cells in HLA-DRB1*11+ patients, in the context of vaccine evaluation. Further phenotypic and functional assessment revealed memory AE37/DR11+CD4+ Τ cells producing mainly Th1 cytokines, containing low number of suppressive regulatory T cells, which are a major concern regarding peptide vaccines that aim to stimulate primarily CD4+ T cells. Similar results regarding the role of preexisting immunity and the expression of HLA-DRB1*11 allele, were also obtained from the analysis in breast cancer patients vaccinated with A37, during the phase II clinical trial. More specifically, vaccinated patients with preexisting HER2 immunity had better overall survival, which was even more prominent in stage III patients. Beside this, in vaccinated patients, the HLA-DRB1*11 allele carriers exhibited better immunologic response to AE37, compared to the non-carriers. In our study, AE37 vaccine might not exert a therapeutic benefit in the total study population, during the specified follow-up period. However, proper stratification of patients might unveil subgroups of patients, who have gained benefit from AE37 vaccination. The findings of this dissertation contribute to the identification of biomarkers, of prognostic and predictive significance in patients’ response, who have received immunotherapy with the AE37 vaccination. At this point, it is important to underline that the current results are based on a small patient population, thus their validation requires larger clinical trials, recruiting a greater number of patients.
Degree
thesis:*- Grantor dc:publisher
- National and Kapodistrian University of Athens
- Year dc:date
- 2016
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Anastasopoulou, Eleftheria
- Αναστασοπούλου, Ελευθερία
Subjects
dc:subject × 6Rights
dc:rights- Statement dc:rights
-
- BY
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/37627